---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113299"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T13:45:33.541732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors

## Summary
- Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.
- Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.
- Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.
- Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge.

## SEC filing metadata
- accession: 0001193125-25-113299
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/0001193125-25-113299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525113299/d923057d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113299
- JSON: https://secwatch.observer/filing/0001193125-25-113299.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.